GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » 5-Year RORE %

Huakang Biomedical Holdings Co (HKSE:08622) 5-Year RORE % : -9.59% (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Huakang Biomedical Holdings Co's 5-Year RORE % for the quarter that ended in Jun. 2024 was -9.59%.

The industry rank for Huakang Biomedical Holdings Co's 5-Year RORE % or its related term are showing as below:

HKSE:08622's 5-Year RORE % is ranked worse than
64.59% of 881 companies
in the Drug Manufacturers industry
Industry Median: 1.85 vs HKSE:08622: -9.59

Huakang Biomedical Holdings Co 5-Year RORE % Historical Data

The historical data trend for Huakang Biomedical Holdings Co's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co 5-Year RORE % Chart

Huakang Biomedical Holdings Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 11.86 20.55 -

Huakang Biomedical Holdings Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.35 7.79 20.55 -9.59 -

Competitive Comparison of Huakang Biomedical Holdings Co's 5-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Huakang Biomedical Holdings Co's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huakang Biomedical Holdings Co's 5-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huakang Biomedical Holdings Co's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Huakang Biomedical Holdings Co's 5-Year RORE % falls into.


;
;

Huakang Biomedical Holdings Co 5-Year RORE % Calculation

Huakang Biomedical Holdings Co's 5-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( -0.074-0 )
=/-0.074
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 5-year before.


Huakang Biomedical Holdings Co  (HKSE:08622) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Huakang Biomedical Holdings Co 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Huakang Biomedical Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.
Executives
Yu Chi Mau 2106 Person having a security interest in shares
Li King Yeung 2106 Person having a security interest in shares
Crystal Grant Limited 2101 Beneficial owner
Arena Investment Management (singapore) Pte Ltd 2102 Investment manager
Arena Investors, Lp 2102 Investment manager
Arena Sg Spv I, Llc 2201 Interest of corporation controlled by you
Tgga, Llc 2106 Person having a security interest in shares
Lau Lai Yee 2201 Interest of corporation controlled by you
Kokusai Resources Company Limited 2101 Beneficial owner
Zhang Shuguang 2101 Beneficial owner
Chang Yim Yang 2401 A concert party to an agreement to buy shares
Ever Charming Inc. 2101 Beneficial owner
Wealthy Pride Investment Limited 2101 Beneficial owner

Huakang Biomedical Holdings Co Headlines

No Headlines